Amedeo Smart

Free Medical Literature Service

 

Amedeo

COVID-19
  Free Subscription

Articles published in
Lancet
    August 2026
  1. SCHWARTZ CA, Weiss Y
    Hate has no place in medicine.
    Lancet. 2026;408:606.
    >> Share

    July 2026
  2. CRIVELLI L, Suemoto CK, Sosa AL, Lopera F, et al
    Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.
    Lancet. 2026 Jul 13:S0140-6736(26)01278-X. doi: 10.1016/S0140-6736(26)01278.
    >> Share

  3. DEZZA FC, Pulido LB, Borreguero IB, Perez FD, et al
    Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTE): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.
    Lancet. 2026 Jul 9:S0140-6736(26)00760-9. doi: 10.1016/S0140-6736(26)00760.
    >> Share

    June 2026
  4. BLAKNEY AK, Top KA, Cowling BJ, Larson HJ, et al
    Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective.
    Lancet. 2026 Jun 30:S0140-6736(26)00512-X. doi: 10.1016/S0140-6736(26)00512.
    >> Share

  5. ABUBAKAR I, Tellez D, Aldridge RW, Altare C, et al
    The UCL-Lancet Commission on Migration and Health: review of the state of progress.
    Lancet. 2026;407:2554-2576.
    >> Share

  6. SASIENI P, Falcaro M
    Cervical cancer mortality trends following HPV vaccination in England, 2001-24: an analysis of population-based mortality data.
    Lancet. 2026 Jun 17:S0140-6736(26)00918-9. doi: 10.1016/S0140-6736(26)00918.
    >> Share


  7. Benzylpenicillin versus flucloxacillin or cloxacillin for the treatment of penicillin-susceptible Staphylococcus aureus bacteraemia (SNAP): an international, multicentre, open-label, non-inferiority randomised controlled trial.
    Lancet. 2026 Jun 17:S0140-6736(26)00761-0. doi: 10.1016/S0140-6736(26)00761.
    >> Share

  8. KARIM SA, Mahomed S, Lewis L, Karim SSA, et al
    Urgent need for a reliable rapid diagnostic test for the Ebola epidemic caused by Bundibugyo virus in Africa.
    Lancet. 2026 Jun 2:S0140-6736(26)01093-7. doi: 10.1016/S0140-6736(26)01093.
    >> Share

    May 2026
  9. GIOVANNONI G, Airas L, Bove R, Cutter GR, et al
    Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study.
    Lancet. 2026;407:2195-2207.
    >> Share

  10. ISLAM MS, Chughtai AA, Wood JG, Sawleshwarkar S, et al
    Hantavirus outbreak on a cruise ship in the South Atlantic.
    Lancet. 2026 May 15:S0140-6736(26)00934-7. doi: 10.1016/S0140-6736(26)00934.
    >> Share

    April 2026
  11. SHANKAR-HARI M, Ming D, Mendelson M, Rupali P, et al
    The Lancet Commission on Sepsis: transforming sepsis care and outcomes.
    Lancet. 2026 Apr 22:S0140-6736(26)00648-3. doi: 10.1016/S0140-6736(26)00648.
    >> Share

    February 2026
  12. NYBERG ST, Frank P, Ahmadi-Abhari S, Pentti J, et al
    Adult obesity and risk of severe infections: a multicohort study with global burden estimates.
    Lancet. 2026 Feb 9:S0140-6736(25)02474-2. doi: 10.1016/S0140-6736(25)02474.
    >> Share

    January 2026
  13. PETO J
    The UK COVID-19 Inquiry and the next pandemic.
    Lancet. 2026;407:220-221.
    >> Share

  14. WHITAKER M, Elliott J, Gerard-Ursin I, Cooke GS, et al
    Profiling vaccine attitudes and subsequent uptake in 1.1 million people in England: a nationwide cohort study.
    Lancet. 2026 Jan 12:S0140-6736(25)01912-9. doi: 10.1016/S0140-6736(25)01912.
    >> Share

    December 2025

  15. Global, regional, and national progress towards the 2030 global nutrition targets and forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2021.
    Lancet. 2025;404:2543-2583.
    >> Share

  16. RUTTER H, Wabnitz K, Nambiar D, Garde A, et al
    The Lancet Commission on improving population health post-COVID-19.
    Lancet. 2025 Dec 11:S0140-6736(25)02061-6. doi: 10.1016/S0140-6736(25)02061.
    >> Share

    November 2025
  17. ZIEGLER AG, Achenbach P, Weiss A, Berner R, et al
    Efficacy of once-daily, high-dose, oral insulin immunotherapy in children genetically at risk for type 1 diabetes (POInT): a European, randomised, placebo-controlled, primary prevention trial.
    Lancet. 2025 Nov 11:S0140-6736(25)01726-X. doi: 10.1016/S0140-6736(25)01726.
    >> Share

  18. MAYER KH, Beyrer C, Cohen MS, El-Sadr WM, et al
    Challenges and opportunities in developing integrated sexual and reproductive health programmes.
    Lancet. 2025;406:2168-2190.
    >> Share

    October 2025
  19. SEDKY J, Gardner A, Ivers LC
    Loans dominated COVID-19 funding: it's time to adjust.
    Lancet. 2025;406:1946.
    >> Share

  20. THE LANCET
    Health progress in a post-COVID-19 world.
    Lancet. 2025 Oct 12:S0140-6736(25)01947-6. doi: 10.1016/S0140-6736(25)01947.
    >> Share


  21. Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.
    Lancet. 2025 Oct 12:S0140-6736(25)01917-8. doi: 10.1016/S0140-6736(25)01917.
    >> Share


  22. Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950-2023: a demographic analysis for the Global Burden of Disease Study 2023.
    Lancet. 2025 Oct 12:S0140-6736(25)01330-3. doi: 10.1016/S0140-6736(25)01330.
    >> Share


  23. Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Stud
    Lancet. 2025 Oct 12:S0140-6736(25)01637-X. doi: 10.1016/S0140-6736(25)01637.
    >> Share

  24. NDEMBI N, Mercy K, Folayan MO, Abdool Karim SS, et al
    Analysis of mpox in Angola conflates distinct timelines.
    Lancet. 2025;406:e29.
    >> Share

  25. REHM J, Assanangkornchai S, Hendershot CS, Franklin A, et al
    Alcohol use disorders.
    Lancet. 2025 Oct 9:S0140-6736(25)01496-5. doi: 10.1016/S0140-6736(25)01496.
    >> Share

  26. RANDERATH W, Grote L, Stenlof K, Fietze I, et al
    Sultiame once per day in obstructive sleep apnoea (FLOW): a multicentre, randomised, double-blind, placebo-controlled, dose-finding, phase 2 trial.
    Lancet. 2025 Oct 9:S0140-6736(25)01196-1. doi: 10.1016/S0140-6736(25)01196.
    >> Share

    September 2025
  27. FRISONI GB, Hansson O, Nichols E, Garibotto V, et al
    New landscape of the diagnosis of Alzheimer's disease.
    Lancet. 2025;406:1389-1407.
    >> Share


  28. The global, regional, and national burden of cancer, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023.
    Lancet. 2025 Sep 24:S0140-6736(25)01635-6. doi: 10.1016/S0140-6736(25)01635.
    >> Share

    August 2025
  29. CHANG AY, Bolongaita S, Cao B, Castro MC, et al
    Epidemiological and demographic trends and projections in global health from 1970 to 2050: a descriptive analysis from the third Lancet Commission on Investing in Health, Global Health 2050.
    Lancet. 2025;406:940-949.
    >> Share

    July 2025

  30. Global HIV targets: a roadmap to 2030 and beyond.
    Lancet. 2025 Jul 16:S0140-6736(25)01449-7. doi: 10.1016/S0140-6736(25)01449.
    >> Share

  31. NEPOGODIEV D, Picciochi M, Ademuyiwa A, Adisa A, et al
    Surgical health policy 2025-35: strengthening essential services for tomorrow's needs.
    Lancet. 2025 Jul 14:S0140-6736(25)00985-7. doi: 10.1016/S0140-6736(25)00985.
    >> Share

  32. WINKLER AS, Brux CM, Carabin H, das Neves CG, et al
    The Lancet One Health Commission: harnessing our interconnectedness for equitable, sustainable, and healthy socioecological systems.
    Lancet. 2025 Jul 14:S0140-6736(25)00627-0. doi: 10.1016/S0140-6736(25)00627.
    >> Share

  33. APEAGYEI AE, Bisignano C, Elliott H, Hay SI, et al
    Tracking development assistance for health, 1990-2030: historical trends, recent cuts, and outlook.
    Lancet. 2025 Jul 14:S0140-6736(25)01240-1. doi: 10.1016/S0140-6736(25)01240.
    >> Share

    June 2025

  34. Global, regional, and national trends in routine childhood vaccination coverage from 1980 to 2023 with forecasts to 2030: a systematic analysis for the Global Burden of Disease Study 2023.
    Lancet. 2025 Jun 24:S0140-6736(25)01037-2. doi: 10.1016/S0140-6736(25)01037.
    >> Share

  35. PAIL O, Lin MJ, Anagnostou T, Brown BD, et al
    Cancer vaccines and the future of immunotherapy.
    Lancet. 2025 Jun 17:S0140-6736(25)00553-7. doi: 10.1016/S0140-6736(25)00553.
    >> Share

    May 2025
  36. KAZATCHKINE M, Liden J
    Seeking an inclusive and just way to simplify the global health architecture.
    Lancet. 2025 May 29:S0140-6736(25)01100-6. doi: 10.1016/S0140-6736(25)01100.
    >> Share

    April 2025
  37. AMOUZOU A, Barros AJD, Requejo J, Faye C, et al
    The 2025 report of the Lancet Countdown to 2030 for women's, children's, and adolescents' health: tracking progress on health and nutrition.
    Lancet. 2025 Apr 9:S0140-6736(25)00151-5. doi: 10.1016/S0140-6736(25)00151.
    >> Share

  38. SUN L, Selbie D, Khan AS, Karim SSA, et al
    Mobilising national and regional assets and non-state actors for pandemic preparedness.
    Lancet. 2025 Apr 3:S0140-6736(25)00630-0. doi: 10.1016/S0140-6736(25)00630.
    >> Share

  39. YUNAS I, Islam MA, Sindhu KN, Devall AJ, et al
    Causes of and risk factors for postpartum haemorrhage: a systematic review and meta-analysis.
    Lancet. 2025 Apr 3:S0140-6736(25)00448-9. doi: 10.1016/S0140-6736(25)00448.
    >> Share

    March 2025
  40. GOSTIN LO, Friedman EA, Dhai A, Zia-Zarifi S, et al
    COVID-19: border closures violate human rights - Authors' reply.
    Lancet. 2025;405:1054.
    >> Share

  41. SILVA DS, Razum O
    COVID-19: border closures violate human rights.
    Lancet. 2025;405:1053-1054.
    >> Share

  42. SINGH B, Lipunga GD, Thangavelu P, Dhar S, et al
    A multifaceted intervention to improve diagnosis and early management of hospitalised patients with suspected acute brain infections in Brazil, India, and Malawi: an international multicentre intervention study.
    Lancet. 2025 Mar 10:S0140-6736(25)00263-6. doi: 10.1016/S0140-6736(25)00263.
    >> Share

  43. WEISS DJ, Dzianach PA, Saddler A, Lubinda J, et al
    Mapping the global prevalence, incidence, and mortality of Plasmodium falciparum and Plasmodium vivax malaria, 2000-22: a spatial and temporal modelling study.
    Lancet. 2025 Mar 5:S0140-6736(25)00038-8. doi: 10.1016/S0140-6736(25)00038.
    >> Share

    February 2025
  44. WONG WC, Lin V, Fang X, Kidd M, et al
    The Lancet Commission on Transforming Primary Health Care in the Post-COVID-19 Era.
    Lancet. 2025 Feb 10:S0140-6736(25)00198-9. doi: 10.1016/S0140-6736(25)00198.
    >> Share

    January 2025
  45. MUMFORD L, Hogg R, Taylor A, Lanyon P, et al
    Impact of SARS-CoV-2 spike antibody positivity on infection and hospitalisation rates in immunosuppressed populations during the omicron period: the MELODY study.
    Lancet. 2025;405:314-328.
    >> Share

  46. KERR S, Robertson C, Sheikh A
    Undervaccination and severe COVID-19 outcomes - Authors' reply.
    Lancet. 2025;405:302.
    >> Share

  47. MORRIS JA
    Undervaccination and severe COVID-19 outcomes.
    Lancet. 2025;405:301-302.
    >> Share

  48. JOFFE AR
    Undervaccination and severe COVID-19 outcomes.
    Lancet. 2025;405:301.
    >> Share

  49. DUNCAN CJA
    Antibody testing to predict SARS-CoV-2 risk in immunocompromised people.
    Lancet. 2025;405:276-278.
    >> Share

  50. THORNTON J
    Every Story Matters: public voices in the COVID-19 Inquiry.
    Lancet. 2025 Jan 14:S0140-6736(25)00095-9. doi: 10.1016/S0140-6736(25)00095.
    >> Share

    December 2024
  51. RUBIN DT, Allegretti JR, Panes J, Shipitofsky N, et al
    Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies.
    Lancet. 2024 Dec 17:S0140-6736(24)01927-5. doi: 10.1016/S0140-6736(24)01927.
    >> Share

  52. DZAU VJ, Laitner MH, Shambaugh EL
    Strategic imperatives for health in the USA: a roadmap for the incoming presidential administration.
    Lancet. 2024;404:2371-2379.
    >> Share


  53. The burden of diseases, injuries, and risk factors by state in the USA, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
    Lancet. 2024;404:2314-2340.
    >> Share

    November 2024
  54. FERRANTE M, D'Haens G, Jairath V, Danese S, et al
    Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.
    Lancet. 2024 Nov 21:S0140-6736(24)01762-8. doi: 10.1016/S0140-6736(24)01762.
    >> Share

  55. DWYER-LINDGREN L, Baumann MM, Li Z, Kelly YO, et al
    Ten Americas: a systematic analysis of life expectancy disparities in the USA.
    Lancet. 2024 Nov 19:S0140-6736(24)01495-8. doi: 10.1016/S0140-6736(24)01495.
    >> Share

  56. DWYER-LINDGREN L, Kendrick P, Baumann MM, Li Z, et al
    Disparities in wellbeing in the USA by race and ethnicity, age, sex, and location, 2008-21: an analysis using the Human Development Index.
    Lancet. 2024 Nov 6:S0140-6736(24)01757-4. doi: 10.1016/S0140-6736(24)01757.
    >> Share

  57. ALWAN NA, Al-Aly Z
    Learning from long COVID: conceptualising action to tackle infection-associated non-communicable diseases.
    Lancet. 2024 Nov 6:S0140-6736(24)02256-6. doi: 10.1016/S0140-6736(24)02256.
    >> Share


  58. Global, regional, and national stillbirths at 20 weeks' gestation or longer in 204 countries and territories, 1990-2021: findings from the Global Burden of Disease Study 2021.
    Lancet. 2024 Nov 4:S0140-6736(24)01925-1. doi: 10.1016/S0140-6736(24)01925.
    >> Share

    October 2024
  59. PAYNE AB, Watts JA, Mitchell PK, Dascomb K, et al
    Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis.
    Lancet. 2024;404:1547-1559.
    >> Share

    September 2024
  60. ROMANELLO M, Costello A
    The Lancet Countdown on health and climate change: competing interests and optimism bias - Authors' reply.
    Lancet. 2024;404:1197-1198.
    >> Share

  61. BRINK N, Chersich MF
    The Lancet Countdown on health and climate change: competing interests and optimism bias.
    Lancet. 2024;404:1196.
    >> Share

  62. BUTLER CD, Combs Bowles D, Hanigan IC, Harmer A, et al
    The Lancet Countdown on health and climate change: competing interests and optimism bias.
    Lancet. 2024;404:1196-1197.
    >> Share

  63. ROMANELLO M, Beggs PJ, Cai W, Gordon-Strachan G, et al
    The Lancet Countdown on health and climate change: representation matters - Authors' reply.
    Lancet. 2024;404:1195-1196.
    >> Share

  64. STREET R, Wright CY
    The Lancet Countdown on health and climate change: representation matters.
    Lancet. 2024;404:1194.
    >> Share

  65. HORTON R
    Offline: Xenotransplantation-a new era beckons.
    Lancet. 2024;404:1181.
    >> Share

  66. ELNAKIB S, Aly S, Asi YM, Shawar YR, et al
    The humanitarian system: politics can not be avoided.
    Lancet. 2024;404:1105-1106.
    >> Share

  67. ST LOUIS P, Makali SL, Paul E
    Health-care workers in fragile and conflict-ridden contexts.
    Lancet. 2024;404:1105.
    >> Share

  68. RAUSEI S, Bertolini AG
    Cuban doctors cannot be the definitive solution for Italy.
    Lancet. 2024;404:1103.
    >> Share

  69. YANG X, Zhang Z, Zhang Z
    Building safe health-care environments in China: urgent challenges.
    Lancet. 2024;404:1101-1102.
    >> Share

  70. HWANG TJ, Trinh QD, Sokolov E
    Safe and equitable use of clinical decision support systems.
    Lancet. 2024;404:1100-1101.
    >> Share

  71. HORTON R
    Offline: From Wanless to Darzi-don't miss this opportunity (again).
    Lancet. 2024;404:1088.
    >> Share

  72. NACHEGA JB, Muyembe-Tamfum JJ, Ntoumi F, Mbala-Kingebeni P, et al
    A call for global solidarity and rapid action to control mpox.
    Lancet. 2024;404:1099-1100.
    >> Share


  73. Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050.
    Lancet. 2024 Sep 13:S0140-6736(24)01867-1. doi: 10.1016/S0140-6736(24)01867.
    >> Share

  74. IMANI-MUSIMWA P, Ververs M
    Mpox and breastmilk: for once, can we act in time?
    Lancet. 2024 Sep 13:S0140-6736(24)01881-6. doi: 10.1016/S0140-6736(24)01881.
    >> Share

    August 2024
  75. MACNAUGHTON J, Zeiler K
    Reimagining illness through post-COVID-19 condition: the need for radically interdisciplinary health research.
    Lancet. 2024;404:840-841.
    >> Share

  76. ZAROCOSTAS J
    Many challenges for WHO-AFRO regional director candidates.
    Lancet. 2024;404:736-737.
    >> Share

  77. BRANDA F, Ceccarelli G, Ciccozzi M, Scarpa F, et al
    Strengthening community resilience: lessons from COVID-19 for mpox prevention.
    Lancet. 2024 Aug 22:S0140-6736(24)01752-5. doi: 10.1016/S0140-6736(24)01752.
    >> Share

  78. DELLGREN JL, Persad G, Emanuel EJ
    International coverage of GLP-1 receptor agonists: a review and ethical analysis of discordant approaches.
    Lancet. 2024 Aug 16:S0140-6736(24)01356-4. doi: 10.1016/S0140-6736(24)01356.
    >> Share

  79. SAMARASEKERA U
    Understanding pandemic risks: the WHO Pandemic Hub.
    Lancet. 2024;404:420-421.
    >> Share

  80. SHAH SA, Robertson C, Sheikh A
    Waiting list models must account for departures before treatment - Authors' reply.
    Lancet. 2024;404:432-433.
    >> Share

  81. WOOD RM
    Waiting list models must account for departures before treatment.
    Lancet. 2024;404:431-432.
    >> Share

  82. O'NEILL D
    Continuing challenges to health equity in Ireland.
    Lancet. 2024;404:431.
    >> Share

  83. BANATVALA JE, Muir P, Irving W, Meader E, et al
    The role of the clinical virologist in pandemic responses.
    Lancet. 2024;404:430.
    >> Share

  84. GARAY J, Kateeb E, Zeballos D, Souza LE, et al
    Inequity in sustainable health today.
    Lancet. 2024;404:429-430.
    >> Share

  85. GREEN A
    Evelyn Fox Keller.
    Lancet. 2024;404:426.
    >> Share

    July 2024
  86. GREENHALGH T, Sivan M, Perlowski A, Nikolich JZ, et al
    Long COVID: a clinical update.
    Lancet. 2024 Jul 31:S0140-6736(24)01136-X. doi: 10.1016/S0140-6736(24)01136.
    >> Share

  87. TRIUNFOL M
    Charges brought in Brazilian COVID-19 malpractice case.
    Lancet. 2024;404:325-326.
    >> Share

  88. BISSONNETTE R, Warren RB, Pinter A, Agner T, et al
    Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials.
    Lancet. 2024 Jul 18:S0140-6736(24)01027-4. doi: 10.1016/S0140-6736(24)01027.
    >> Share

  89. FRANZ C, Holzscheiter A, Kickbusch I
    Germany's role in global health at a critical juncture.
    Lancet. 2024;404:82-94.
    >> Share

    June 2024
  90. SAMARASEKERA U
    No parties meeting the challenge on health in the UK.
    Lancet. 2024;403:2769-2770.
    >> Share

  91. DIEDRICH L
    Illness politics and social media mobilisation.
    Lancet. 2024;403:2776-2777.
    >> Share

  92. THE LANCET
    UK elections: the need for a healthy change.
    Lancet. 2024;403:2755.
    >> Share

  93. GARCIA PJ, Saavedra J, Espinoza-Pajuelo L, Garcia-Terron FA, et al
    Why Latin America needs a regional Centre for Disease Control and Prevention.
    Lancet. 2024;403:2763-2765.
    >> Share

  94. HIRST JE, Witt A, Mullins E, Womersley K, et al
    Delivering the promise of improved health for women and girls in England.
    Lancet. 2024 Jun 27:S0140-6736(24)01347-3. doi: 10.1016/S0140-6736(24)01347.
    >> Share

  95. HO A, Galgut O, Faustini S, Peters N, et al
    Implications of suboptimal measles immunity in UK health-care workers.
    Lancet. 2024 Jun 26:S0140-6736(24)01011-0. doi: 10.1016/S0140-6736(24)01011.
    >> Share

  96. SCHRECKER T
    Canada's reckoning?
    Lancet. 2024;403:2688.
    >> Share

  97. ZAROCOSTAS J
    Mental health in emergencies requires "a major rethink".
    Lancet. 2024;403:2582.
    >> Share

  98. AHSAN S
    Israel border closure denying health care to Gazans.
    Lancet. 2024;403:2581.
    >> Share

  99. SAMARASEKERA U
    African vaccine manufacturing scheme to boost production.
    Lancet. 2024;403:2579-2580.
    >> Share

  100. KUNKLER I
    Improving future UK pandemic management structure.
    Lancet. 2024;403:2592.
    >> Share

  101. YOON JH, Kwon IH, Park HW
    The South Korean health-care system in crisis.
    Lancet. 2024;403:2589.
    >> Share

  102. THE LANCET
    Taking persistent physical symptoms seriously.
    Lancet. 2024;403:2565.
    >> Share

  103. MCCALL C
    Security concerns threaten Papua New Guinea relief efforts.
    Lancet. 2024;403:2471.
    >> Share

  104. KOMAMURA K, Iwase M
    Clinical outcomes of the AdaptResponse trial.
    Lancet. 2024;403:2484.
    >> Share

  105. FILIPPATOS G, Gold MR, Mullens W, Kusano K, et al
    Clinical outcomes of the AdaptResponse trial - Authors' reply.
    Lancet. 2024;403:2484-2485.
    >> Share

  106. HORTON R
    Offline: The system is not working.
    Lancet. 2024;403:2470.
    >> Share

  107. MOHAPATRA PR
    Responding to India's data and transparency.
    Lancet. 2024;403:2482-2483.
    >> Share

  108. ANIRVAN P
    Blowing in the wind-India's health data and transparency issues.
    Lancet. 2024;403:2483-2484.
    >> Share

  109. KELLY P, Lemmens R, Weimar C, Walsh C, et al
    Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke (CONVINCE): a randomised controlled trial.
    Lancet. 2024 Jun 7:S0140-6736(24)00968-1. doi: 10.1016/S0140-6736(24)00968.
    >> Share

  110. WATTS G
    Martin Raw.
    Lancet. 2024;403:2372.
    >> Share

  111. SAMARASEKERA U
    Calls for a focus on health risks in EU election.
    Lancet. 2024;403:2364.
    >> Share

  112. TORNINI VA, Fernandez RW, Goldman OV, Suarez J, et al
    DEI infrastructures required for the best science and medicine.
    Lancet. 2024;403:2375.
    >> Share

  113. HORTON R
    Offline: UK election-two issues you won't hear about.
    Lancet. 2024;403:2362.
    >> Share

    May 2024
  114. PATERLINI M
    Warnings over Italian health-care devolution.
    Lancet. 2024;403:2279.
    >> Share

  115. THORNTON J
    Infected blood report release marks a day of shame for the UK.
    Lancet. 2024;403:2276-2277.
    >> Share

  116. THE LANCET
    Cyberattacks on health care-a growing threat.
    Lancet. 2024;403:2263.
    >> Share

  117. KIMBALL AB, Jemec GBE, Sayed CJ, Kirby JS, et al
    Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.
    Lancet. 2024 May 22:S0140-6736(24)00101-6. doi: 10.1016/S0140-6736(24)00101.
    >> Share

  118. LAXMINARAYAN R, Impalli I, Rangarajan R, Cohn J, et al
    Expanding antibiotic, vaccine, and diagnostics development and access to tackle antimicrobial resistance.
    Lancet. 2024 May 20:S0140-6736(24)00878-X. doi: 10.1016/S0140-6736(24)00878.
    >> Share

  119. SAMARASEKERA U
    50 years of the Expanded Programme on Immunization.
    Lancet. 2024;403:1971-1972.
    >> Share


  120. Burden of disease scenarios for 204 countries and territories, 2022-2050: a forecasting analysis for the Global Burden of Disease Study 2021.
    Lancet. 2024;403:2204-2256.
    >> Share

  121. MARCATO AJ, Meagher N, Spirkoska V, Arnott A, et al
    One Health pandemic preparedness: the role of companion animals in disease transmission.
    Lancet. 2024;403:1984-1985.
    >> Share

  122. ADAMU AA, Ndwandwe D, Jalo RI, Muhammad ID, et al
    Cofinancing immunisation through national health insurance.
    Lancet. 2024;403:1983-1984.
    >> Share

  123. HORTON R
    Offline: Indifference-the biggest threat to global health.
    Lancet. 2024;403:1970.
    >> Share

  124. KANTER R, Fort MP
    Rethinking health policy: life expectancy and mortality in an era of polycrisis.
    Lancet. 2024;403:1956-1958.
    >> Share

  125. WATTS G
    Alasdair Macintosh Geddes.
    Lancet. 2024;403:1846.
    >> Share

  126. AUJLA M
    Art, plunder, fragile fault lines.
    Lancet. 2024;403:1844-1845.
    >> Share

  127. USHER AD
    Organisations vie for control over pandemic financing.
    Lancet. 2024;403:1839-1840.
    >> Share

  128. GREENHALGH T, MacIntyre CR, Ungrin M, Wright JM, et al
    Airborne pathogens: controlling words won't control transmission.
    Lancet. 2024;403:1850-1851.
    >> Share

  129. YANG YT
    Protecting humanitarian aid workers: an urgent call.
    Lancet. 2024;403:1847.
    >> Share

  130. ABUZERR S, Zinser K
    Amplifying the voices of women in the Gaza Strip.
    Lancet. 2024;403:1848-1849.
    >> Share

  131. KNUPPEL A, Boyd A, Macleod J, Chaturvedi N, et al
    The long COVID evidence gap in England.
    Lancet. 2024 May 6:S0140-6736(24)00744-X. doi: 10.1016/S0140-6736(24)00744.
    >> Share

  132. KIVIMAKI M, Batty GD
    Work as a health risk.
    Lancet. 2024;403:1747-1748.
    >> Share

    April 2024
  133. GREEN A
    Tobias Welte.
    Lancet. 2024;403:1626.
    >> Share

  134. ADEPOJU P
    Moderna stalls on African vaccine manufacturing plans.
    Lancet. 2024;403:1617.
    >> Share

  135. MARCHALIK D, Rehm D
    On not cutting corners.
    Lancet. 2024;403:1623.
    >> Share

  136. DEVI S
    Swedish NGOs are reeling after government cuts.
    Lancet. 2024;403:1527.
    >> Share


  137. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a sys
    Lancet. 2024 Apr 15:S0140-6736(24)00757-8. doi: 10.1016/S0140-6736(24)00757.
    >> Share

  138. ZUMLA A, Peiris M, Memish ZA, Perlman S, et al
    Anticipating a MERS-like coronavirus as a potential pandemic threat.
    Lancet. 2024 Apr 8:S0140-6736(24)00641-X. doi: 10.1016/S0140-6736(24)00641.
    >> Share

  139. PETO L, Basnyat B, Horby P
    High-dose corticosteroid therapy in COVID-19: the RECOVERY trial - Authors' reply.
    Lancet. 2024;403:1339-1340.
    >> Share

  140. BHUSAL S, Adhikari S
    High-dose corticosteroid therapy in COVID-19: the RECOVERY trial.
    Lancet. 2024;403:1339.
    >> Share

  141. NARASARAJU T, Ravi Y, Jonsson CB, Chow VTK, et al
    High-dose corticosteroid therapy in COVID-19: the RECOVERY trial.
    Lancet. 2024;403:1338-1339.
    >> Share

  142. HSU NC, Tokuda Y
    High-dose corticosteroid therapy in COVID-19: the RECOVERY trial.
    Lancet. 2024;403:1338.
    >> Share

  143. MCEVOY N, Lowry J, O'Dowd A, Curley GF, et al
    High-dose corticosteroid therapy in COVID-19: the RECOVERY trial.
    Lancet. 2024;403:1337.
    >> Share

  144. HASHIM Z, Nath A, Tripathy NK
    High-dose corticosteroid therapy in COVID-19: the RECOVERY trial.
    Lancet. 2024;403:1337-1338.
    >> Share

  145. SORAAS A, Brunvoll SH, Nygaard AB, Dahl JA, et al
    Post-COVID-19 condition symptoms 6-12 months after hospitalisation in Wuhan.
    Lancet. 2024;403:1336.
    >> Share

  146. GU X, Huang L, Zhang H, Cao B, et al
    Post-COVID-19 condition symptoms 6-12 months after hospitalisation in Wuhan - Authors' reply.
    Lancet. 2024;403:1336-1337.
    >> Share


  147. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
    Lancet. 2024 Apr 3:S0140-6736(24)00367-2. doi: 10.1016/S0140-6736(24)00367.
    >> Share

    March 2024
  148. KULKARNI PS, Potey AV, Bharati S, Kunhihitlu A, et al
    The safety and immunogenicity of a bivalent conjugate vaccine against Salmonella enterica Typhi and Paratyphi A in healthy Indian adults: a phase 1, randomised, active-controlled, double-blind trial.
    Lancet. 2024 Mar 28:S0140-6736(24)00249-6. doi: 10.1016/S0140-6736(24)00249.
    >> Share

  149. SZANYI J, Howe S, Blakely T
    The importance of reporting accurate estimates of long COVID prevalence.
    Lancet. 2024;403:1136-1137.
    >> Share

  150. WENHAM C, Stout L
    A legal mapping of 48 WHO member states' inclusion of public health emergency of international concern, pandemic, and health emergency terminology within national emergency legislation in responding to health emergencies.
    Lancet. 2024 Mar 22:S0140-6736(24)00156-9. doi: 10.1016/S0140-6736(24)00156.
    >> Share

  151. SHAWE-TAYLOR M, Greenwood D, Hobbs A, Dowgier G, et al
    Divergent performance of vaccines in the UK autumn 2023 COVID-19 booster campaign.
    Lancet. 2024 Mar 11:S0140-6736(24)00316-7. doi: 10.1016/S0140-6736(24)00316.
    >> Share


  152. Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950-2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden
    Lancet. 2024 Mar 8:S0140-6736(24)00476-8. doi: 10.1016/S0140-6736(24)00476.
    >> Share

  153. PARHIZ H, Atochina-Vasserman EN, Weissman D
    mRNA-based therapeutics: looking beyond COVID-19 vaccines.
    Lancet. 2024 Mar 7:S0140-6736(23)02444-3. doi: 10.1016/S0140-6736(23)02444.
    >> Share

    February 2024
  154. DHAIRYAWAN R
    Candour, care, and COVID-19.
    Lancet. 2024;403:718.
    >> Share

  155. VORA NM, Hassan L, Plowright RK, Horton R, et al
    The Lancet-PPATS Commission on Prevention of Viral Spillover: reducing the risk of pandemics through primary prevention.
    Lancet. 2024;403:597-599.
    >> Share

  156. WALLER BY, Joseph VA, Keyes KM
    Racial inequities in homicide rates and homicide methods among Black and White women aged 25-44 years in the USA, 1999-2020: a cross-sectional time series study.
    Lancet. 2024 Feb 8:S0140-6736(23)02279-1. doi: 10.1016/S0140-6736(23)02279.
    >> Share

    January 2024
  157. MCCLOSKEY B, Saito T, Shimada S, Ikenoue C, et al
    The Tokyo 2020 and Beijing 2022 Olympic Games held during the COVID-19 pandemic: planning, outcomes, and lessons learnt.
    Lancet. 2024 Jan 17:S0140-6736(23)02635-1. doi: 10.1016/S0140-6736(23)02635.
    >> Share

  158. WANG L, Wang Q, Gao GF
    Interpreting COVID-19 data from China: a call for caution - Authors' reply.
    Lancet. 2024;403:144-145.
    >> Share

  159. QU Z
    Interpreting COVID-19 data from China: a call for caution.
    Lancet. 2024;403:144.
    >> Share

  160. GULLIFORD MC, Steves CJ
    Access to COVID-19 vaccination and COVID-19-related hospital admissions and mortality.
    Lancet. 2024 Jan 12:S0140-6736(23)02622-3. doi: 10.1016/S0140-6736(23)02622.
    >> Share


  161. Undervaccination and severe COVID-19 outcomes: meta-analysis of national cohort studies in England, Northern Ireland, Scotland, and Wales.
    Lancet. 2024 Jan 12:S0140-6736(23)02467-4. doi: 10.1016/S0140-6736(23)02467.
    >> Share

  162. SHAH SA, Robertson C, Sheikh A
    Effects of the COVID-19 pandemic on NHS England waiting times for elective hospital care: a modelling study.
    Lancet. 2024 Jan 11:S0140-6736(23)02744-7. doi: 10.1016/S0140-6736(23)02744.
    >> Share

    December 2023

  163. How modelling can better support public health policy making: the Lancet Commission on Strengthening the Use of Epidemiological Modelling of Emerging and Pandemic Infectious Diseases.
    Lancet. 2023 Dec 20:S0140-6736(23)02758-7. doi: 10.1016/S0140-6736(23)02758.
    >> Share

  164. GILES-VERNICK T, Cheah PY, Matta G, Lima NT, et al
    Louis Pasteur, COVID-19, and the social challenges of epidemics.
    Lancet. 2023;400:2166-2168.
    >> Share

  165. CHARLIER P
    Death and end of life in France after COVID-19.
    Lancet. 2023;402:2290.
    >> Share

  166. HORTON R
    Offline: Boris Johnson and COVID-19-more light than heat.
    Lancet. 2023;402:2277.
    >> Share

    November 2023
  167. POESPOPRODJO JR, Douglas NM, Ansong D, Kho S, et al
    Malaria.
    Lancet. 2023 Nov 1:S0140-6736(23)01249-7. doi: 10.1016/S0140-6736(23)01249.
    >> Share

  168. ZIAUDDEEN N, Pantelic M, O'Hara ME, Hastie C, et al
    Impact of long COVID-19 on work: a co-produced survey.
    Lancet. 2023;402 Suppl 1:S98.
    >> Share

  169. VAN YPEREN J, Campillo-Funollet E, Memon A, Allman P, et al
    The Sussex COVID-19 Modelling Cell: the methods and successes of a collaboration between public health teams in local authorities, NHS hospital trusts, NHS commissioners, and universities.
    Lancet. 2023;402 Suppl 1:S94.
    >> Share

  170. WRENN K, Blomquist PB, Inzoungou-Massanga C, Olufon O, et al
    Surge of lower respiratory tract group A streptococcal infections in England in winter 2022: epidemiology and clinical profile.
    Lancet. 2023;402 Suppl 1:S93.
    >> Share

  171. RAMASAWMY M, Khan N, Sunkersing D, Banerjee A, et al
    Understanding ethnic inequalities in the design and implementation of digital health interventions for cardiometabolic disease: a qualitative study.
    Lancet. 2023;402 Suppl 1:S78.
    >> Share


  172. Nowcasting waiting lists for elective procedures and surgery in England: a modelling study.
    Lancet. 2023;402 Suppl 1:S74.
    >> Share

  173. MURPHY MH, O'Kane SM, Carlin A, Lahart IM, et al
    A peer-led walking intervention for adolescent girls (the WISH study): a cluster-randomised controlled trial.
    Lancet. 2023;402 Suppl 1:S72.
    >> Share

  174. MORENO-AGOSTINO D, Das-Munshi J, Ploubidis GB
    Differences in the impact of the COVID-19 pandemic in the long-term trajectories of life satisfaction by sex in the UK: a prospective cohort study.
    Lancet. 2023;402 Suppl 1:S71.
    >> Share

  175. MARTIN A, Jamieson S
    Exploring the experiences of junior doctors who were shielding during the COVID-19 pandemic: a qualitative study of semi-structured interviews.
    Lancet. 2023;402 Suppl 1:S68.
    >> Share

  176. KROMYDAS T, Demou E, Leyland AH, Katikireddi SV, et al
    Effect of trade unions on the mental health of UK workers before and during the COVID-19 pandemic: a longitudinal analysis using Understanding Society data.
    Lancet. 2023;402 Suppl 1:S62.
    >> Share

  177. KHAN Y, Verhaeghe N, Devleesschauwer B, Cavillot L, et al
    Impact of the COVID-19 pandemic on delayed care of cardiovascular diseases in Europe: a systematic review.
    Lancet. 2023;402 Suppl 1:S61.
    >> Share

  178. KALBUS A, Cornelsen L, Ballatore A, Cummins S, et al
    Changes in food and drink purchasing behaviour in England during the first 3 months of the COVID-19 pandemic: an interrupted time-series analysis.
    Lancet. 2023;402 Suppl 1:S60.
    >> Share

  179. HINDOCHA A, Brennan L, Brewster L, Lunn J, et al
    The wider health and wellbeing needs of those accessing paediatric care in England: engaging with the hidden voices of children and young people.
    Lancet. 2023;402 Suppl 1:S50.
    >> Share

  180. HAZIR SG, Ryan C, Moore A, Lewis C, et al
    The role of the multiple Index of deprivation in predicting mental health outcomes after the COVID-19 pandemic in adolescents: a cross-sectional study.
    Lancet. 2023;402 Suppl 1:S47.
    >> Share

  181. DU Z, Wang L, Bai Y, Pei Y, et al
    Mitigation of respiratory syncytial virus epidemics by RSVpreF vaccines after the COVID-19 pandemic in the UK: a modelling study.
    Lancet. 2023;402 Suppl 1:S39.
    >> Share

  182. DOBBIN J, Soares CA, Burns F, Miall N, et al
    Medical consequences of "contingency accommodation" for people seeking asylum: thematic analysis of a survey from professionals working in contingency accommodation.
    Lancet. 2023;402 Suppl 1:S38.
    >> Share

  183. ARNOTT J, Troya MI, Joyce M, Khashan A, et al
    Untangling the association between COVID-19 health literacy, trust in the pandemic response, and mental distress, during the COVID-19 pandemic in Ireland: a repeated cross-sectional study.
    Lancet. 2023;402 Suppl 1:S23.
    >> Share

  184. ACHARYA A, Darzi A, Judah G
    An SMS and animated video intervention to increase uptake of breast cancer screening: a randomised controlled trial.
    Lancet. 2023;402 Suppl 1:S17.
    >> Share

    October 2023
  185. WANG Q, Bowen A, Ho J, Zhang RM, et al
    SARS-CoV-2 neutralising antibodies after a second BA.5 bivalent booster.
    Lancet. 2023 Oct 31:S0140-6736(23)02278-X. doi: 10.1016/S0140-6736(23)02278.
    >> Share

  186. ABBASI K, Ali P, Barbour V, Benfield T, et al
    Time to treat the climate and nature crisis as one indivisible global health emergency.
    Lancet. 2023 Oct 25:S0140-6736(23)02289-4. doi: 10.1016/S0140-6736(23)02289.
    >> Share

  187. FRANK J, Mustard C, Smith P, Siddiqi A, et al
    Work as a social determinant of health in high-income countries: past, present, and future.
    Lancet. 2023;402:1357-1367.
    >> Share

  188. DELFRAISSY JF, Horgan M, Molbak K, Simon FS, et al
    Scientific advisory councils in the COVID-19 response.
    Lancet. 2023 Oct 12:S0140-6736(23)01846-9. doi: 10.1016/S0140-6736(23)01846.
    >> Share

    September 2023
  189. HOCHMAYR C, Kiechl-Kohlendorfer U, Griesmaier E
    COVID toes, newborn blue toes, and prepartum SARS-CoV-2 infection - Authors' reply.
    Lancet. 2023;402:1132.
    >> Share

  190. MATUCHANSKY C
    Natural SARS-CoV-2 infection-induced immune protection against re-infection.
    Lancet. 2023;402:1131.
    >> Share

  191. ZHOU YB, Xu ZG
    COVID toes, newborn blue toes, and prepartum SARS-CoV-2 infection.
    Lancet. 2023;402:1131-1132.
    >> Share

  192. QU Z
    Cautionary notes on the COVID-19 re-infection study.
    Lancet. 2023;402:1130-1131.
    >> Share

  193. FLACCO ME, Martellucci CA, Manzoli L
    Extra data to confirm waning protection of omicron (B.1.1.529) natural immunity.
    Lancet. 2023;402:1129.
    >> Share

  194. YANG C, Lapp L, Tebbutt SJ
    Overcoming COVID-19 vaccine hesitancy hurdles.
    Lancet. 2023;402:1129-1130.
    >> Share

  195. TSAGKARIS C, Papazoglou AS, Moysidis DV, Papadakos SP, et al
    Striving to afford free health care in Greece during COVID-19.
    Lancet. 2023;402:1128-1129.
    >> Share

  196. PALUMBO L, Picchio CA, Smallwood C, Salvi C, et al
    Community COVID-19 response in WHO's European region.
    Lancet. 2023;402:1127.
    >> Share

  197. UMAR TP
    Arcturus (XBB.1.16) COVID-19 subvariant emergence in Indonesia.
    Lancet. 2023;402:1127-1128.
    >> Share

  198. JASSAT W, Reyes LF, Munblit D, Caoili J, et al
    Long COVID in low-income and middle-income countries: the hidden public health crisis.
    Lancet. 2023;402:1115-1117.
    >> Share

  199. MASSUDA A, Dall'Alba R, Chioro A, Temporao JG, et al
    Bolsonaro's Ministry of Health's response to COVID-19 and other health challenges - Authors' reply.
    Lancet. 2023;402:1041-1042.
    >> Share

  200. PARENTE RCM, Queiroga M
    Bolsonaro's Ministry of Health's response to COVID-19 and other health challenges.
    Lancet. 2023;402:1040-1041.
    >> Share

  201. ZHANG H
    COVID-19 and Chinese nurses' mental health.
    Lancet. 2023;402:1039-1040.
    >> Share

  202. HEYMANS S, Lakdawala NK, Tschope C, Klingel K, et al
    Dilated cardiomyopathy: causes, mechanisms, and current and future treatment approaches.
    Lancet. 2023;402:998-1011.
    >> Share

  203. DZAU V, Swaminathan S, Baker C, Bright RA, et al
    The 100 Days Mission: how a new medical-countermeasures network can deliver equity and innovation.
    Lancet. 2023 Sep 5:S0140-6736(23)01775-0. doi: 10.1016/S0140-6736(23)01775.
    >> Share

  204. PERCIVAL V, Thoms OT, Oppenheim B, Rowlands D, et al
    The Lancet Commission on peaceful societies through health equity and gender equality.
    Lancet. 2023 Sep 4:S0140-6736(23)01348-X. doi: 10.1016/S0140-6736(23)01348.
    >> Share

    August 2023
  205. DAI L, Duan H, Liu X, Zhou H, et al
    Omicron neutralisation: RBD-dimer booster versus BF.7 and BA.5.2 breakthrough infection.
    Lancet. 2023;402:687-689.
    >> Share

  206. KUNG S, Hills T, Kearns N, Beasley R, et al
    New Zealand's COVID-19 elimination strategy and mortality patterns.
    Lancet. 2023 Aug 24:S0140-6736(23)01368-5. doi: 10.1016/S0140-6736(23)01368.
    >> Share

  207. IFTEKHAR N, Sivan M
    Venous insufficiency and acrocyanosis in long COVID: dysautonomia.
    Lancet. 2023;402:e9.
    >> Share

  208. KNAUL FM, Arreola-Ornelas H, Touchton M, McDonald T, et al
    Setbacks in the quest for universal health coverage in Mexico: polarised politics, policy upheaval, and pandemic disruption.
    Lancet. 2023 Aug 7:S0140-6736(23)00777-8. doi: 10.1016/S0140-6736(23)00777.
    >> Share

    July 2023
  209. HSU NC, Hsu CH
    COVID-19 and commerce complicate minimum unit pricing effects on health.
    Lancet. 2023;402:368.
    >> Share

  210. WYPER GM, Mackay DF, Fraser C, Lewsey J, et al
    COVID-19 and commerce complicate minimum unit pricing effects on health - Authors' reply.
    Lancet. 2023;402:368-369.
    >> Share


  211. Pandemics move faster than funders.
    Lancet. 2023;402:367.
    >> Share

  212. ZHOU J, Zhang Y, Mo K, Newbert H, et al
    mRNA vaccines do not stop with COVID-19.
    Lancet. 2023 Jul 27:S0140-6736(23)01514-3. doi: 10.1016/S0140-6736(23)01514.
    >> Share

  213. O'BRIEN KL, Lemango E
    The big catch-up in immunisation coverage after the COVID-19 pandemic: progress and challenges to achieving equitable recovery.
    Lancet. 2023 Jul 17:S0140-6736(23)01468-X. doi: 10.1016/S0140-6736(23)01468.
    >> Share

  214. RIFE EC, Cron RQ
    Janus kinase inhibition in juvenile idiopathic arthritis.
    Lancet. 2023 Jul 6:S0140-6736(23)01134-0. doi: 10.1016/S0140-6736(23)01134.
    >> Share

    June 2023

  215. The unfinished agenda of communicable diseases among children and adolescents before the COVID-19 pandemic, 1990-2019: a systematic analysis of the Global Burden of Disease Study 2019.
    Lancet. 2023 Jun 29:S0140-6736(23)00860-7. doi: 10.1016/S0140-6736(23)00860.
    >> Share

  216. WIJAYA R, Johnson M, Campbell N, Stuart B, et al
    Predicting COVID-19 infection risk in people who are immunocompromised by antibody testing.
    Lancet. 2023 Jun 29:S0140-6736(23)01180-7. doi: 10.1016/S0140-6736(23)01180.
    >> Share

  217. PELOSI A
    Disrespectful language about patients with long COVID.
    Lancet. 2023;401:2108.
    >> Share

  218. PRIYA GIRI S, Dubey A
    Loneliness in the time of COVID-19: an alarming rise.
    Lancet. 2023;401:2107-2108.
    >> Share

  219. BAILEY C, Sanderson T, Townsley H, Goldman J, et al
    Independent SARS-CoV-2 staff testing protected academic and health-care institutions in northwest London.
    Lancet. 2023 Jun 19:S0140-6736(23)00917-0. doi: 10.1016/S0140-6736(23)00917.
    >> Share

  220. LEGIDO-QUIGLEY H, Clark H, Nishtar S, Horton R, et al
    Reimagining health security and preventing future pandemics: the NUS-Lancet Pandemic Readiness, Implementation, Monitoring, and Evaluation Commission.
    Lancet. 2023;401:2021-2023.
    >> Share

  221. HUANG C, Huang L, Wang Y, Li X, et al
    6-month consequences of COVID-19 in patients discharged from hospital: a cohort study.
    Lancet. 2023 Jun 12:S0140-6736(23)00810-3. doi: 10.1016/S0140-6736(23)00810.
    >> Share

  222. PLATZBECKER U, Della Porta MG, Santini V, Zeidan AM, et al
    Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
    Lancet. 2023 Jun 9:S0140-6736(23)00874-7. doi: 10.1016/S0140-6736(23)00874.
    >> Share

  223. THE LANCET EDITORS
    Retraction and republication: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study.
    Lancet. 2023 Jun 9:S0140-6736(23)01175-3. doi: 10.1016/S0140-6736(23)01175.
    >> Share

  224. WOLF J, Johnston RB, Ambelu A, Arnold BF, et al
    Burden of disease attributable to unsafe drinking water, sanitation, and hygiene in domestic settings: a global analysis for selected adverse health outcomes.
    Lancet. 2023 Jun 5:S0140-6736(23)00458-0. doi: 10.1016/S0140-6736(23)00458.
    >> Share

    May 2023
  225. JAFFE S
    US health experts divided on social media age restrictions.
    Lancet. 2023;401:1757.
    >> Share


  226. Learning from serosurveillance for SARS-CoV-2 to inform pandemic preparedness and response.
    Lancet. 2023 May 26:S0140-6736(23)00964-9. doi: 10.1016/S0140-6736(23)00964.
    >> Share

  227. FLAHAULT A, Calmy A, Costagliola D, Drapkina O, et al
    No time for complacency on COVID-19 in Europe.
    Lancet. 2023 May 22:S0140-6736(23)01012-7. doi: 10.1016/S0140-6736(23)01012.
    >> Share

  228. ZAROCOSTAS J
    With the COVID-19 PHEIC over, what next?
    Lancet. 2023;401:1642-1643.
    >> Share

  229. MFINANGA SG, Gatei W, Tinuga F, Mwengee WMP, et al
    Tanzania's COVID-19 vaccination strategy: lessons, learning, and execution.
    Lancet. 2023;401:1649.
    >> Share

  230. JAFFE S
    US Surgeon General: loneliness is a public health crisis.
    Lancet. 2023;401:1560.
    >> Share

  231. EMANUEL EJ, Persad G
    The shared ethical framework to allocate scarce medical resources: a lesson from COVID-19.
    Lancet. 2023 May 9:S0140-6736(23)00812-7. doi: 10.1016/S0140-6736(23)00812.
    >> Share

    April 2023
  232. AGRAWAL U, Robertson C, Sheikh A
    Moving towards a precision approach for prevention of severe COVID-19 - Authors' reply.
    Lancet. 2023;401:1424.
    >> Share

  233. BRANCH-ELLIMAN W, Monach PA
    Moving towards a precision approach for prevention of severe COVID-19.
    Lancet. 2023;401:1423-1424.
    >> Share

  234. SZAPOCZNIK J, Faviero G, Dansua AS, Bausch DG, et al
    The importance of accountability in tackling future pandemics.
    Lancet. 2023;401:1423.
    >> Share

  235. GALVAO J
    COVID-19: forgetting a pandemic that is not over.
    Lancet. 2023;401:1422-1423.
    >> Share

  236. THE LANCET
    Moving past the COVID-19 emergency in the USA.
    Lancet. 2023;401:1399.
    >> Share

  237. ROSS I, Bick S, Ayieko P, Dreibelbis R, et al
    Effectiveness of handwashing with soap for preventing acute respiratory infections in low-income and middle-income countries: a systematic review and meta-analysis.
    Lancet. 2023 Apr 27:S0140-6736(23)00021-1. doi: 10.1016/S0140-6736(23)00021.
    >> Share

  238. CUENI T
    Lessons learned from COVID-19 to stop future pandemics.
    Lancet. 2023;401:1340.
    >> Share

  239. HORTON R
    Offline: The UK COVID-19 Inquiry-be patient, but don't wait.
    Lancet. 2023;401:1324.
    >> Share

  240. LURIE N, Sharfstein JM
    State-to-state differences in US COVID-19 outcomes: searching for explanations.
    Lancet. 2023;401:1314-1315.
    >> Share

  241. PETROV AN, Dorough DS, Tiwari S, Welford M, et al
    Indigenous health-care sovereignty defines resilience to the COVID-19 pandemic.
    Lancet. 2023 Apr 18:S0140-6736(23)00684-0. doi: 10.1016/S0140-6736(23)00684.
    >> Share

  242. HOCHMAYR C, Auckenthaler M, Fink FM, Kiechl-Kohlendorfer U, et al
    Differential diagnosis of blue toes in a newborn baby: might have been maternal infection with COVID-19?
    Lancet. 2023;401:e20.
    >> Share

  243. GOH AXC, Chae SR, Chiew CJ, Tang N, et al
    Characteristics of the omicron XBB subvariant wave in Singapore.
    Lancet. 2023;401:1261-1262.
    >> Share

  244. KING B, Zhang X, Harcha WG, Szepietowski JC, et al
    Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial.
    Lancet. 2023 Apr 13:S0140-6736(23)00222-2. doi: 10.1016/S0140-6736(23)00222.
    >> Share


  245. Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
    Lancet. 2023 Apr 12:S0140-6736(23)00510-X. doi: 10.1016/S0140-6736(23)00510.
    >> Share

  246. PERNER A, Venkatesh B
    Higher-dose dexamethasone for patients with COVID-19 and hypoxaemia?
    Lancet. 2023 Apr 12:S0140-6736(23)00587-1. doi: 10.1016/S0140-6736(23)00587.
    >> Share

    March 2023
  247. THE EDITORS OF THE LANCET
    Retraction-Chinese medical personnel after the COVID-19 pandemic.
    Lancet. 2023;401:1141.
    >> Share

  248. SUN L, Jia H, Yang T
    Chinese medical personnel after the COVID-19 pandemic.
    Lancet. 2023;401:1000.
    >> Share

  249. FRIEL S, Collin J, Daube M, Depoux A, et al
    Commercial determinants of health: future directions.
    Lancet. 2023 Mar 22:S0140-6736(23)00011-9. doi: 10.1016/S0140-6736(23)00011.
    >> Share

  250. GILMORE AB, Fabbri A, Baum F, Bertscher A, et al
    Defining and conceptualising the commercial determinants of health.
    Lancet. 2023 Mar 22:S0140-6736(23)00013-2. doi: 10.1016/S0140-6736(23)00013.
    >> Share

  251. BOLLYKY TJ, Castro E, Aravkin AY, Bhangdia K, et al
    Assessing COVID-19 pandemic policies and behaviours and their economic and educational trade-offs across US states from Jan 1, 2020, to July 31, 2022: an observational analysis.
    Lancet. 2023 Mar 22:S0140-6736(23)00461-0. doi: 10.1016/S0140-6736(23)00461.
    >> Share


  252. Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis.
    Lancet. 2023;401:833-842.
    >> Share

  253. COHEN C, Pulliam J
    COVID-19 infection, reinfection, and the transition to endemicity.
    Lancet. 2023;401:798-800.
    >> Share

  254. QU Z
    International cooperation to end the COVID-19 pandemic.
    Lancet. 2023;401:820.
    >> Share

  255. THE LANCET
    Long COVID: 3 years in.
    Lancet. 2023;401:795.
    >> Share

  256. CARPIANO RM, Callaghan T, DiResta R, Brewer NT, et al
    Confronting the evolution and expansion of anti-vaccine activism in the USA in the COVID-19 era.
    Lancet. 2023 Mar 2:S0140-6736(23)00136-8. doi: 10.1016/S0140-6736(23)00136.
    >> Share

    February 2023
  257. HUANG S, Gao Z, Wang S
    China's COVID-19 reopening measures-warriors and weapons.
    Lancet. 2023;401:643-644.
    >> Share

  258. HAY SI, Murray CJL
    Conflicting COVID-19 excess mortality estimates - Authors' reply.
    Lancet. 2023;401:433-434.
    >> Share

  259. BAGER P, Nielsen J, Bhatt S, Nielsen LB, et al
    Conflicting COVID-19 excess mortality estimates.
    Lancet. 2023;401:432-433.
    >> Share

  260. DONZELLI A
    Conflicting COVID-19 excess mortality estimates.
    Lancet. 2023;401:432.
    >> Share

  261. MOETI M, Makubalo L, Gueye AS, Balde T, et al
    Conflicting COVID-19 excess mortality estimates.
    Lancet. 2023;401:431.
    >> Share

  262. O'NEILL D
    Conflicting COVID-19 excess mortality estimates.
    Lancet. 2023;401:431.
    >> Share

  263. SCHOLEY J, Karlinsky A, Kobak D, Tallack C, et al
    Conflicting COVID-19 excess mortality estimates.
    Lancet. 2023;401:431-432.
    >> Share

  264. PAN Y, Wang L, Feng Z, Xu H, et al
    Characterisation of SARS-CoV-2 variants in Beijing during 2022: an epidemiological and phylogenetic analysis.
    Lancet. 2023 Feb 8:S0140-6736(23)00129-0. doi: 10.1016/S0140-6736(23)00129.
    >> Share

  265. PREISER W, Maponga T
    So far, no novel SARS-CoV-2 variants from Beijing-and hopefully better scientific cooperation going forward.
    Lancet. 2023 Feb 8:S0140-6736(23)00268-4. doi: 10.1016/S0140-6736(23)00268.
    >> Share

  266. TAN H, Liu J, Zeng F
    China needs a scientific long COVID recovery-support platform.
    Lancet. 2023;401:344-345.
    >> Share

    January 2023
  267. MOHEBBI N, Ritter A, Wiegand A, Graf N, et al
    Sodium bicarbonate for kidney transplant recipients with metabolic acidosis in Switzerland: a multicentre, randomised, single-blind, placebo-controlled, phase 3 trial.
    Lancet. 2023 Jan 25:S0140-6736(22)02606-X. doi: 10.1016/S0140-6736(22)02606.
    >> Share

  268. ELNAIEM A, Mohamed-Ahmed O, Zumla A, Mecaskey J, et al
    Global and regional governance of One Health and implications for global health security.
    Lancet. 2023 Jan 19:S0140-6736(22)01597-5. doi: 10.1016/S0140-6736(22)01597.
    >> Share

  269. TRAORE T, Shanks S, Haider N, Ahmed K, et al
    How prepared is the world? Identifying weaknesses in existing assessment frameworks for global health security through a One Health approach.
    Lancet. 2023 Jan 19:S0140-6736(22)01589-6. doi: 10.1016/S0140-6736(22)01589.
    >> Share

  270. MWATONDO A, Rahman-Shepherd A, Hollmann L, Chiossi S, et al
    A global analysis of One Health Networks and the proliferation of One Health collaborations.
    Lancet. 2023 Jan 19:S0140-6736(22)01596-3. doi: 10.1016/S0140-6736(22)01596.
    >> Share

  271. ELLINGTON S, Jatlaoui TC
    COVID-19 vaccination is effective at preventing severe illness and complications during pregnancy.
    Lancet. 2023 Jan 17:S0140-6736(22)02613-7. doi: 10.1016/S0140-6736(22)02613.
    >> Share

  272. VILLAR J, Soto Conti CP, Gunier RB, Ariff S, et al
    Pregnancy outcomes and vaccine effectiveness during the period of omicron as the variant of concern, INTERCOVID-2022: a multinational, observational study.
    Lancet. 2023 Jan 17:S0140-6736(22)02467-9. doi: 10.1016/S0140-6736(22)02467.
    >> Share

  273. THE LANCET
    The COVID-19 pandemic in 2023: far from over.
    Lancet. 2023;401:79.
    >> Share

  274. BAKER MG, Durrheim D, Hsu LY, Wilson N, et al
    COVID-19 and other pandemics require a coherent response strategy.
    Lancet. 2023 Jan 13:S0140-6736(22)02489-8. doi: 10.1016/S0140-6736(22)02489.
    >> Share

    December 2022
  275. TIBBLE H, Mueller T, Proud E, Hall E, et al
    Uptake of monoclonal antibodies and antiviral therapies for COVID-19 in Scotland.
    Lancet. 2022 Dec 22:S0140-6736(22)02398-4. doi: 10.1016/S0140-6736(22)02398.
    >> Share

  276. KIDD MR, Kelly PM
    PANORAMIC: important insights into molnupiravir use in COVID-19.
    Lancet. 2022 Dec 22:S0140-6736(22)02593-4. doi: 10.1016/S0140-6736(22)02593.
    >> Share

  277. BUTLER CC, Hobbs FDR, Gbinigie OA, Rahman NM, et al
    Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial.
    Lancet. 2022 Dec 22:S0140-6736(22)02597-1. doi: 10.1016/S0140-6736(22)02597.
    >> Share

  278. SELVARAJAH S, Corona Maioli S, Deivanayagam TA, de Morais Sato P, et al
    Racism, xenophobia, and discrimination: mapping pathways to health outcomes.
    Lancet. 2022;400:2109-2124.
    >> Share

  279. DEVAKUMAR D, Selvarajah S, Abubakar I, Kim SS, et al
    Racism, xenophobia, discrimination, and the determination of health.
    Lancet. 2022;400:2097-2108.
    >> Share

  280. ELSON W, Zambon M, de Lusignan S
    Integrated respiratory surveillance after the COVID-19 pandemic.
    Lancet. 2022;400:1924-1925.
    >> Share

    November 2022
  281. THE LANCET EDITORS
    Expression of concern: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study.
    Lancet. 2022 Nov 24:S0140-6736(22)02370-4. doi: 10.1016/S0140-6736(22)02370.
    >> Share

  282. HORTON R
    Offline: COVID-19-the lessons that science forgot.
    Lancet. 2022;400:1753.
    >> Share


  283. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019.
    Lancet. 2022 Nov 18:S0140-6736(22)02185-7. doi: 10.1016/S0140-6736(22)02185.
    >> Share

  284. GOSTIN LO, Friedman EA, Hossain S, Mukherjee J, et al
    Human rights and the COVID-19 pandemic: a retrospective and prospective analysis.
    Lancet. 2022 Nov 17:S0140-6736(22)01278-8. doi: 10.1016/S0140-6736(22)01278.
    >> Share

  285. OWEN A, Diaz JV, Guyatt G, Lamontagne F, et al
    WHO Living Guidelines on antivirals for COVID-19 are evidence-based.
    Lancet. 2022 Nov 10. pii: S0140-6736(22)02306.
    >> Share

  286. KALRA PR, Cleland JGF, Petrie MC, Thomson EA, et al
    Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial.
    Lancet. 2022 Nov 4. pii: S0140-6736(22)02083.
    >> Share

  287. DOWRICK A, Rai T, Hinton L, Eacott B, et al
    Health inequalities, ethnic minorities and COVID19: interactive theatre workshop drawing on a qualitative interview study.
    Lancet. 2022;400 Suppl 1:S9.
    >> Share

  288. ZURIAGA A, Flannigan L, Wilson J, Weiss S, et al
    A partnership approach to supporting the health and wellbeing of the Charedi (Orthodox Jewish) community in London.
    Lancet. 2022;400 Suppl 1:S85.
    >> Share

  289. PANTELIC M, Ziauddeen N, Boyes M, O'Hara ME, et al
    The prevalence of stigma in a UK community survey of people with lived experience of long COVID.
    Lancet. 2022;400 Suppl 1:S84.
    >> Share

  290. TWEED S
    Experience of homelessness during the COVID-19 pandemic in Tower Hamlets, London: a health needs assessment.
    Lancet. 2022;400 Suppl 1:S82.
    >> Share

  291. TURNER G, de'Donato F, Kovats S, Hoeben A, et al
    Implementation of adaptation to climate change in public health in Europe: qualitative thematic analysis.
    Lancet. 2022;400 Suppl 1:S81.
    >> Share

  292. TORRESIN S, Ratcliffe E, Aletta F, Albatici R, et al
    The effect of indoor soundscape on sexual wellbeing during the COVID-19 lockdown in London: a thematic analysis of remote workers' experiences.
    Lancet. 2022;400 Suppl 1:S80.
    >> Share

  293. SCOTT S, McGowan VJ, Wildman JM, Bidmead E, et al
    COVID-19 and the role of Voluntary, Community, and Social Enterprises in northern England in responding to the needs of marginalised communities: a qualitative focus group study.
    Lancet. 2022;400 Suppl 1:S78.
    >> Share

  294. SERKA S, Mainwaring J
    Perspectives of education and mental health professionals on adolescent school-based mental health promotion: a qualitative exploration.
    Lancet. 2022;400 Suppl 1:S76.
    >> Share

  295. ROSENTHAL DM, Heys M, Schoenthaler A, Hayward A, et al
    How did living in temporary accommodation during the COVID-19 pandemic affect children younger than 5 years' access to health care and health outcomes? A qualitative study of key professionals in a socially and ethnically diverse and deprived area of
    Lancet. 2022;400 Suppl 1:S75.
    >> Share

  296. QI C, Osborne T, Bailey R, Hollinghurst J, et al
    Effect of the COVID-19 pandemic on incidence of long-term conditions in Welsh residents: a population linkage study.
    Lancet. 2022;400 Suppl 1:S69.
    >> Share

  297. NIRANJAN V, Fitzpatrick P, Morrogh R, O'Hagan K, et al
    Evaluation of community outreach feasibility programmes on improving cancer-related, preventive, health behaviour.
    Lancet. 2022;400 Suppl 1:S67.
    >> Share

  298. MCQUIRE C, Zuccolo L, Frennesson F, Butcher S, et al
    Prenatal alcohol prevention in the UK: mapping the landscape through systematic collaborative review.
    Lancet. 2022;400 Suppl 1:S64.
    >> Share

  299. MCKINLAY AR, Collins L, Fancourt D, Burton A, et al
    How did female survivors of abuse use the arts to support their mental health and wellbeing during the COVID-19 pandemic? A qualitative exploration of their views.
    Lancet. 2022;400 Suppl 1:S63.
    >> Share

  300. PARNHAM JC, Vamos EP, McKevitt S, Laverty AA, et al
    The UK's Free School Meals policy during the pandemic: a thematic content analysis of policy documents and debates.
    Lancet. 2022;400 Suppl 1:S62.
    >> Share

  301. TINNER L
    Exploring young people's perceptions of health and inequality through art: a co-produced qualitative study.
    Lancet. 2022;400 Suppl 1:S6.
    >> Share

  302. MAKANJUOLA A, Lynch M, Hartfiel N, Cuthbert A, et al
    Social return on investment of face-to-face versus online lifestyle coaching to improve mental wellbeing.
    Lancet. 2022;400 Suppl 1:S59.
    >> Share

  303. KEEBLE M, Adams J, Burgoine T
    Changes in online food access during the COVID-19 pandemic and associations with deprivation: a longitudinal analysis.
    Lancet. 2022;400 Suppl 1:S54.
    >> Share

  304. BURNS R, Campos-Matos I, Harron K, Aldridge RW, et al
    COVID-19 vaccination uptake for half a million non-EU migrants and refugees in England: a linked retrospective population-based cohort study.
    Lancet. 2022;400 Suppl 1:S5.
    >> Share

  305. GRAY BJ, Kyle RG, Challenger A, Davies AR, et al
    Mental health of the nursing and midwifery workforce in Wales during the COVID-19 pandemic: a cross-sectional analysis.
    Lancet. 2022;400 Suppl 1:S43.
    >> Share

  306. HUF SW, Woldmann L, Crespo RF, Grailey K, et al
    Implementing behavioural science informed letter interventions to increase COVID-19 vaccination uptake in uncontactable London residents: a difference-in-difference study in London, UK.
    Lancet. 2022;400 Suppl 1:S41.
    >> Share

  307. GEISMAR C, Nguyen V, Fragaszy E, Shrotri M, et al
    Bayesian reconstruction of household transmissions to infer the serial interval of COVID-19 by variants of concern: analysis from a prospective community cohort study (Virus Watch).
    Lancet. 2022;400 Suppl 1:S40.
    >> Share

  308. DAWES J, May T, Fancourt D, Burton A, et al
    The impact of the COVID-19 pandemic on people experiencing homelessness: a qualitative interview study in the UK.
    Lancet. 2022;400 Suppl 1:S35.
    >> Share

  309. CURTIN EL, Widnall E, Dodd S, Limmer M, et al
    The Peer Education Project to improve mental health literacy in secondary school students in England: a qualitative realist evaluation.
    Lancet. 2022;400 Suppl 1:S34.
    >> Share

  310. BRIGHT D, Song J, Hillier S, Huws DW, et al
    Impact of the temporary suspension of the Bowel Screening Wales programme on inequalities during the COVID-19 pandemic: a retrospective register-based study.
    Lancet. 2022;400 Suppl 1:S25.
    >> Share

  311. BEYNON C
    Exploring the association between obesity and problems with peer relationships in children: a nationally representative cross-sectional study.
    Lancet. 2022;400 Suppl 1:S21.
    >> Share

  312. BERNARD A, Salhi L, de Ossorno Garcia S, John A, et al
    Engagement of individuals aged 14-25 years with a digital mental health service during the COVID-19 pandemic in the UK: a cohort study of service usage data.
    Lancet. 2022;400 Suppl 1:S20.
    >> Share

  313. ANDREAE G, Scott S, Nguyen G, Bell Z, et al
    Food insecurity among pregnant women living in high-income countries: a systematic review.
    Lancet. 2022;400 Suppl 1:S17.
    >> Share

  314. GRIFFITHS ML, Gray BJ, Kyle RG, Davies AR, et al
    Shifting priorities and employment choices among workers in Wales during the COVID-19 pandemic: a longitudinal analysis.
    Lancet. 2022;400 Suppl 1:S1.
    >> Share

    October 2022

  315. Elective surgery system strengthening: development, measurement, and validation of the surgical preparedness index across 1632 hospitals in 119 countries.
    Lancet. 2022 Oct 31. pii: S0140-6736(22)01846.
    >> Share

  316. FRENK J, Chen LC, Chandran L, Groff EOH, et al
    Challenges and opportunities for educating health professionals after the COVID-19 pandemic.
    Lancet. 2022;400:1539-1556.
    >> Share

  317. DAS M, Keke K
    Pandemic solidarity across national borders saved lives.
    Lancet. 2022;400:1510-1511.
    >> Share

  318. AGUS DB, Nguyen A, Sall AA, Bell J, et al
    COVID-19 and other adult vaccines can drive global disease prevention.
    Lancet. 2022 Oct 27. pii: S0140-6736(22)02084.
    >> Share

  319. OPEL DJ, Brewer NT, Buttenheim AM, Callaghan T, et al
    The legacy of the COVID-19 pandemic for childhood vaccination in the USA.
    Lancet. 2022 Oct 26. pii: S0140-6736(22)01693.
    >> Share

  320. LEFRANCOIS T, Malvy D, Atlani-Duault L, Benamouzig D, et al
    After 2 years of the COVID-19 pandemic, translating One Health into action is urgent.
    Lancet. 2022 Oct 21. pii: S0140-6736(22)01840.
    >> Share

  321. AGRAWAL U, Bedston S, McCowan C, Oke J, et al
    Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales.
    Lancet. 2022;400:1305-1320.
    >> Share

  322. MSELLATI P, Sow K, Desclaux A, Cottrell G, et al
    Reconsidering the COVID-19 vaccine strategy in West and Central Africa.
    Lancet. 2022;400:1304.
    >> Share

  323. IRVING SA, Sundaram ME
    Prioritisation of COVID-19 boosters in the omicron era.
    Lancet. 2022;400:1282-1283.
    >> Share

  324. WONG CKH, Au ICH, Lau KTK, Lau EHY, et al
    Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kon
    Lancet. 2022;400:1213-1222.
    >> Share

  325. BURDET C, Ader F
    Real-world effectiveness of oral antivirals for COVID-19.
    Lancet. 2022;400:1175-1176.
    >> Share

  326. FRENK J, Godal T, Gomez-Dantes O, Store JG, et al
    A reinvigorated multilateralism in health: lessons and innovations from the COVID-19 pandemic.
    Lancet. 2022 Oct 7. pii: S0140-6736(22)01943.
    >> Share

  327. WU MY, Carr EJ, Harvey R, Mears HV, et al
    WHO's Therapeutics and COVID-19 Living Guideline on mAbs needs to be reassessed.
    Lancet. 2022 Oct 6. pii: S0140-6736(22)01938.
    >> Share

    September 2022
  328. HAMEED SS, Hall E, Grange Z, Sullivan C, et al
    Characterising adults in Scotland who are not vaccinated against COVID-19.
    Lancet. 2022;400:993-995.
    >> Share

  329. THE LANCET
    COVID-19: the case for prosociality.
    Lancet. 2022 Sep 14. pii: S0140-6736(22)01761.
    >> Share

  330. SACHS JD, Karim SSA, Aknin L, Allen J, et al
    The Lancet Commission on lessons for the future from the COVID-19 pandemic.
    Lancet. 2022 Sep 14. pii: S0140-6736(22)01585.
    >> Share

  331. YEK C, Warner S, Mancera A, Kadri SS, et al
    Misclassification bias in estimating clinical severity of SARS-CoV-2 variants.
    Lancet. 2022;400:809.
    >> Share

  332. NYBERG T, Ferguson NM, Blake J, Hinsley W, et al
    Misclassification bias in estimating clinical severity of SARS-CoV-2 variants - Authors' reply.
    Lancet. 2022;400:809-810.
    >> Share

  333. ZHANG Y, Wang Y, Ning G, He P, et al
    Protecting older people: a high priority during the COVID-19 pandemic.
    Lancet. 2022;400:729-730.
    >> Share

  334. THORNTON J
    New centre for pandemic therapeutics.
    Lancet. 2022;400:722.
    >> Share

  335. GORMAN EA, O'Kane CM, McAuley DF
    Acute respiratory distress syndrome in adults: diagnosis, outcomes, long-term sequelae, and management.
    Lancet. 2022 Sep 2. pii: S0140-6736(22)01439.
    >> Share

    August 2022
  336. UYEKI TM, Hui DS, Zambon M, Wentworth DE, et al
    Influenza.
    Lancet. 2022;400:693-706.
    >> Share

  337. BOLLYKY TJ, Angelino O, Wigley S, Dieleman JL, et al
    Trust made the difference for democracies in COVID-19.
    Lancet. 2022;400:657.
    >> Share

  338. MOETI M, Gao GF, Herrman H
    Global pandemic perspectives: public health, mental health, and lessons for the future.
    Lancet. 2022;400:e3-e7.
    >> Share


  339. The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the Global Burden of Disease Study 2019.
    Lancet. 2022;400:563-591.
    >> Share

  340. HILL M, Bandyopadhyay AS, Pollard AJ
    Emergence of vaccine-derived poliovirus in high-income settings in the absence of oral polio vaccine use.
    Lancet. 2022 Aug 18. pii: S0140-6736(22)01582.
    >> Share

  341. BALLERING AV, van Zon SKR, Olde Hartman TC, Rosmalen JGM, et al
    Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study.
    Lancet. 2022;400:452-461.
    >> Share

  342. SORENSEN RJD
    COVID-19 and microbiome diversity in sub-Saharan Africa - Author's reply.
    Lancet. 2022;400:429-430.
    >> Share

  343. VAN DAMME W, Wamai R, Assefa Y, Liesenborghs L, et al
    COVID-19 and microbiome diversity in sub-Saharan Africa.
    Lancet. 2022;400:429.
    >> Share

  344. BRIGHTLING CE, Evans RA
    Long COVID: which symptoms can be attributed to SARS-CoV-2 infection?
    Lancet. 2022;400:411-413.
    >> Share

    July 2022

  345. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
    Lancet. 2022;400:359-368.
    >> Share

  346. THORNTON J
    Violence against health workers rises during COVID-19.
    Lancet. 2022;400:348.
    >> Share

  347. MEHTA P, Titanji BK
    Baricitinib in COVID-19: a coming-of-age from artificial intelligence to reducing mortality.
    Lancet. 2022;400:338-339.
    >> Share

  348. LAWTON T, Alwan NA
    The UK COVID-19 Inquiry must examine the foundations of pandemic decision making.
    Lancet. 2022 Jul 18. pii: S0140-6736(22)01332.
    >> Share


  349. Population-level risks of alcohol consumption by amount, geography, age, sex, and year: a systematic analysis for the Global Burden of Disease Study 2020.
    Lancet. 2022;400:185-235.
    >> Share

  350. MESSACAR K, Baker RE, Park SW, Nguyen-Tran H, et al
    Preparing for uncertainty: endemic paediatric viral illnesses after COVID-19 pandemic disruption.
    Lancet. 2022 Jul 14. pii: S0140-6736(22)01277.
    >> Share

  351. DURRHEIM DN
    Perilous two-tier COVID-19 global vaccine roll-out.
    Lancet. 2022 Jul 11. pii: S0140-6736(22)01284.
    >> Share

  352. WOLTER N, Jassat W, von Gottberg A, Cohen C, et al
    Clinical severity of omicron lineage BA.2 infection compared with BA.1 infection in South Africa.
    Lancet. 2022;400:93-96.
    >> Share

  353. MELLO MM, Opel DJ, Benjamin RM, Callaghan T, et al
    Effectiveness of vaccination mandates in improving uptake of COVID-19 vaccines in the USA.
    Lancet. 2022 Jul 8. pii: S0140-6736(22)00875.
    >> Share

  354. GOGA A, Bekker LG, Garrett N, Reddy T, et al
    Breakthrough SARS-CoV-2 infections during periods of delta and omicron predominance, South Africa.
    Lancet. 2022 Jul 6. pii: S0140-6736(22)01190.
    >> Share

  355. NASSIRI-ANSARI T, Atuhebwe P, Ayisi AS, Goulding S, et al
    Shifting gender barriers in immunisation in the COVID-19 pandemic response and beyond.
    Lancet. 2022;400:24.
    >> Share

  356. PFAFF F, Hoffmann D, Beer M
    Monkeypox genomic surveillance will challenge lessons learned from SARS-CoV-2.
    Lancet. 2022;400:22-23.
    >> Share

    June 2022
  357. SACCO C, Del Manso M, Mateo-Urdiales A, Rota MC, et al
    Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis of January-April, 2022.
    Lancet. 2022 Jun 30. pii: S0140-6736(22)01185.
    >> Share

  358. LADHANI SN
    COVID-19 vaccination for children aged 5-11 years.
    Lancet. 2022 Jun 30. pii: S0140-6736(22)01245.
    >> Share

  359. BURKI T
    COVID-19 in North Korea.
    Lancet. 2022;399:2339.
    >> Share

  360. ANTONELLI M, Pujol JC, Spector TD, Ourselin S, et al
    Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2.
    Lancet. 2022;399:2263-2264.
    >> Share

  361. OFRI D
    Memorialising COVID-19.
    Lancet. 2022;399:2260-2261.
    >> Share

  362. LI G, Cappuccini F, Marchevsky NG, Aley PK, et al
    Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
    Lancet. 2022;399:2212-2225.
    >> Share

  363. WONG HL, Hu M, Zhou CK, Lloyd PC, et al
    Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases.
    Lancet. 2022;399:2191-2199.
    >> Share

  364. PATEL M, Patel M
    Increasing children's global access to COVID-19 vaccines.
    Lancet. 2022;399:2171-2173.
    >> Share

  365. HUSBY A, Kober L
    COVID-19 mRNA vaccination and myocarditis or pericarditis.
    Lancet. 2022;399:2168-2169.
    >> Share

    May 2022
  366. CLARK H, Cardenas M, Dybul M, Kazatchkine M, et al
    Transforming or tinkering: the world remains unprepared for the next pandemic threat.
    Lancet. 2022;399:1995-1999.
    >> Share

  367. NELLUMS LB, Latif A, Nkhoma K, Timmons S, et al
    COVID-19 boosters and building trust among UK minority ethnic communities.
    Lancet. 2022 May 25. pii: S0140-6736(22)00945.
    >> Share

  368. DENNEHY JJ, Gupta RK, Hanage WP, Johnson MC, et al
    Where is the next SARS-CoV-2 variant of concern?
    Lancet. 2022;399:1938-1939.
    >> Share

  369. KICKBUSCH I, Liu A
    Global health diplomacy-reconstructing power and governance.
    Lancet. 2022 May 17. pii: S0140-6736(22)00583.
    >> Share

  370. YUAN S
    Zero COVID in China: what next?
    Lancet. 2022;399:1856-1857.
    >> Share

  371. SHERLOCK PL
    COVID-19 and inter-generational solidarity.
    Lancet. 2022;399:1775.
    >> Share

  372. THE LANCET
    COVID-19: the next phase and beyond.
    Lancet. 2022;399:1753.
    >> Share

  373. BHUTTA ZA, Boerma T, Black MM, Victora CG, et al
    Optimising child and adolescent health and development in the post-pandemic world.
    Lancet. 2022;399:1759-1761.
    >> Share

  374. JHA P, Brown PE, Ansumana R
    Counting the global COVID-19 dead.
    Lancet. 2022 May 6. pii: S0140-6736(22)00845.
    >> Share

  375. ZHANG X, Zhang W, Chen S
    Shanghai's life-saving efforts against the current omicron wave of the COVID-19 pandemic.
    Lancet. 2022 May 6. pii: S0140-6736(22)00838.
    >> Share

  376. CHRISTENSON SA, Smith BM, Bafadhel M, Putcha N, et al
    Chronic obstructive pulmonary disease.
    Lancet. 2022 May 6. pii: S0140-6736(22)00470.
    >> Share

  377. DZAU VJ, Balatbat CA, Offodile AC 2nd
    Closing the global vaccine equity gap: equitably distributed manufacturing.
    Lancet. 2022 May 6. pii: S0140-6736(22)00793.
    >> Share


  378. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses.
    Lancet. 2022 May 2. pii: S0140-6736(22)00519.
    >> Share

    April 2022
  379. ADEPOJU P
    Africa CDC warns COVID-19 vaccine production could cease.
    Lancet. 2022;399:1683.
    >> Share

  380. VICTORA CG, Hartwig FP, Vidaletti LP, Martorell R, et al
    Effects of early-life poverty on health and human capital in children and adolescents: analyses of national surveys and birth cohort studies in LMICs.
    Lancet. 2022;399:1741-1752.
    >> Share

  381. ARCHARD D, Buyx A, Delfraissy JF
    Responding to the humanitarian crisis of the war in Ukraine with lessons from COVID-19.
    Lancet. 2022 Apr 25. pii: S0140-6736(22)00731.
    >> Share

  382. GRAMMATOPOULOS DK, Young L, Anderson NR
    Transforming the UK's diagnostics agenda after COVID-19.
    Lancet. 2022;399:1606.
    >> Share

  383. JEFFORD M, Howell D, Li Q, Lisy K, et al
    Improved models of care for cancer survivors.
    Lancet. 2022;399:1551-1560.
    >> Share

  384. FISHER D, Suri S, Carson G
    What comes next in the COVID-19 pandemic?
    Lancet. 2022 Apr 11. pii: S0140-6736(22)00580.
    >> Share

  385. BUCHBINDER SP, McElrath MJ, Dieffenbach C, Corey L, et al
    COVID-19 vaccination and HIV-1 acquisition - Authors' reply.
    Lancet. 2022;399:e36.
    >> Share

  386. LOGUNOV DY, Livermore DM, Ornelles DA, Bayer W, et al
    COVID-19 vaccination and HIV-1 acquisition.
    Lancet. 2022;399:e34-e35.
    >> Share

  387. DWEK RA, Bell JI, Feldmann M, Zitzmann N, et al
    Host-targeting oral antiviral drugs to prevent pandemics.
    Lancet. 2022;399:1381-1382.
    >> Share


  388. Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis.
    Lancet. 2022 Apr 8. pii: S0140-6736(22)00484.
    >> Share

  389. SHIODA K, Lopman B
    How to interpret the total number of SARS-CoV-2 infections.
    Lancet. 2022 Apr 8. pii: S0140-6736(22)00629.
    >> Share

  390. MENNI C, Valdes AM, Polidori L, Antonelli M, et al
    Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study.
    Lancet. 2022 Apr 7. pii: S0140-6736(22)00327.
    >> Share

  391. HAN X, Li J, Chen Y, Li Y, et al
    SARS-CoV-2 nucleic acid testing is China's key pillar of COVID-19 containment.
    Lancet. 2022 Apr 7. pii: S0140-6736(22)00577.
    >> Share

  392. BERGMARK BA, Mathenge N, Merlini PA, Lawrence-Wright MB, et al
    Acute coronary syndromes.
    Lancet. 2022;399:1347-1358.
    >> Share

  393. KHOBRAGADE A, Bhate S, Ramaiah V, Deshpande S, et al
    Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India.
    Lancet. 2022;399:1313-1321.
    >> Share

  394. ZAROCOSTAS J
    Mixed response to COVID-19 intellectual property waiver.
    Lancet. 2022;399:1292-1293.
    >> Share

  395. BLAKNEY AK, Bekker LG
    DNA vaccines join the fight against COVID-19.
    Lancet. 2022;399:1281-1282.
    >> Share

  396. POST LA, Lorenzo-Redondo R
    Omicron: fewer adverse outcomes come with new dangers.
    Lancet. 2022;399:1280-1281.
    >> Share

    March 2022
  397. LUKE JJ, Rutkowski P, Queirolo P, Del Vecchio M, et al
    Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.
    Lancet. 2022 Mar 31. pii: S0140-6736(22)00562.
    >> Share


  398. NCD Countdown 2030: efficient pathways and strategic investments to accelerate progress towards the Sustainable Development Goal target 3.4 in low-income and middle-income countries.
    Lancet. 2022;399:1266-1278.
    >> Share

  399. KRAUSE PR, Rees H, Figueroa JP, Swaminathan S, et al
    Booster vaccines for COVID-19 vaccine breakthrough cases? - Authors' reply.
    Lancet. 2022;399:1225.
    >> Share

  400. NIXON DF, Schwartz RE, Ndhlovu LC
    Booster vaccines for COVID-19 vaccine breakthrough cases?
    Lancet. 2022;399:1224.
    >> Share

  401. SWETS MC, Russell CD, Harrison EM, Docherty AB, et al
    SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses.
    Lancet. 2022 Mar 25. pii: S0140-6736(22)00383.
    >> Share

  402. KOLA L, Kumar M, Kohrt BA, Fatodun T, et al
    Strengthening public mental health during and after the acute phase of the COVID-19 pandemic.
    Lancet. 2022 Mar 24. pii: S0140-6736(22)00523.
    >> Share

  403. WATERS L, Marra F, Pozniak A, Cockburn J, et al
    Ritonavir and COVID-19: pragmatic guidance is important.
    Lancet. 2022 Mar 22. pii: S0140-6736(22)00280.
    >> Share

  404. BEKKER LG, Garrett N, Goga A, Fairall L, et al
    Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study.
    Lancet. 2022;399:1141-1153.
    >> Share

  405. PREISER W, Fish T
    Sisonke: reaching several goals together.
    Lancet. 2022;399:1095-1097.
    >> Share

  406. NYBERG T, Ferguson NM, Nash SG, Webster HH, et al
    Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study.
    Lancet. 2022 Mar 16. pii: S0140-6736(22)00462.
    >> Share

  407. REARTE A, Castelli JM, Rearte R, Fuentes N, et al
    Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study.
    Lancet. 2022 Mar 15. pii: S0140-6736(22)00011.
    >> Share

  408. MILLS EJ, Reis G
    Evaluating COVID-19 vaccines in the real world.
    Lancet. 2022 Mar 15. pii: S0140-6736(22)00194.
    >> Share

  409. YEN HL, Sit THC, Brackman CJ, Chuk SSY, et al
    Transmission of SARS-CoV-2 delta variant (AY.127) from pet hamsters to humans, leading to onward human-to-human transmission: a case study.
    Lancet. 2022;399:1070-1078.
    >> Share

  410. HAAGMANS BL, Koopmans MPG
    Spreading of SARS-CoV-2 from hamsters to humans.
    Lancet. 2022;399:1027-1028.
    >> Share

  411. KHAN W, Abubakar A, Brennan RJ, Al Hosani F, et al
    Preparing for future pandemics in the Eastern Mediterranean region.
    Lancet. 2022;399:1032-1033.
    >> Share

  412. ABUBAKAR I, Dalglish SL, Angell B, Sanuade O, et al
    The Lancet Nigeria Commission: investing in health and the future of the nation.
    Lancet. 2022 Mar 11. pii: S0140-6736(21)02488.
    >> Share

  413. ANGELL B, Sanuade O, Adetifa IMO, Okeke IN, et al
    Population health outcomes in Nigeria compared with other west African countries, 1998-2019: a systematic analysis for the Global Burden of Disease Study.
    Lancet. 2022 Mar 11. pii: S0140-6736(21)02722.
    >> Share


  414. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21.
    Lancet. 2022 Mar 10. pii: S0140-6736(21)02796.
    >> Share

  415. MANCA T, Baylis F, Munoz FM, Top KA, et al
    Prioritise research on vaccines for pregnant and breastfeeding women.
    Lancet. 2022;399:890-893.
    >> Share

  416. FALLAH MP, Reinhart E
    Apartheid logic in global health.
    Lancet. 2022;399:902-903.
    >> Share

  417. CORREIA LCL, Sette C, Santos M, Magliano CAS, et al
    Brazil's COVID-19 guidelines: political hijack of public health.
    Lancet. 2022 Mar 3. pii: S0140-6736(22)00338.
    >> Share

  418. KUCHARSKI AJ, Jit M, Logan JG, Cotten M, et al
    Travel measures in the SARS-CoV-2 variant era need clear objectives.
    Lancet. 2022 Mar 2. pii: S0140-6736(22)00366.
    >> Share

  419. FLOR LS, Friedman J, Spencer CN, Cagney J, et al
    Quantifying the effects of the COVID-19 pandemic on gender equality on health, social, and economic indicators: a comprehensive review of data from March, 2020, to September, 2021.
    Lancet. 2022 Mar 2. pii: S0140-6736(22)00008.
    >> Share

  420. MORGAN R, Pimenta DN, Rashid S
    Gender equality and COVID-19: act now before it is too late.
    Lancet. 2022 Mar 2. pii: S0140-6736(22)00278.
    >> Share

    February 2022
  421. USHER AD
    The global COVID-19 treatment divide.
    Lancet. 2022;399:779-782.
    >> Share

  422. CHEMAITELLY H, Abu-Raddad LJ
    Waning effectiveness of COVID-19 vaccines.
    Lancet. 2022;399:771-773.
    >> Share

  423. THE LANCET
    Our commitment to help accelerate progress against cancer.
    Lancet. 2022;399:769.
    >> Share


  424. Variation in the COVID-19 infection-fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis.
    Lancet. 2022 Feb 24. pii: S0140-6736(21)02867.
    >> Share

  425. GU X, Cao B
    Understanding of COVID-19 from infection-fatality ratio.
    Lancet. 2022 Feb 24. pii: S0140-6736(22)00281.
    >> Share

  426. BAJAJ SS, Maki L, Stanford FC
    Vaccine apartheid: global cooperation and equity.
    Lancet. 2022 Feb 23. pii: S0140-6736(22)00328.
    >> Share

  427. ADAMS LV, Dorough DS
    Accelerating Indigenous health and wellbeing: the Lancet Commission on Arctic and Northern Health.
    Lancet. 2022;399:613-614.
    >> Share

  428. BURKI T
    Fresh questions over Gates Foundation governance.
    Lancet. 2022;399:508.
    >> Share

  429. HUMPHREYS K, Shover CL, Andrews CM, Bohnert ASB, et al
    Responding to the opioid crisis in North America and beyond: recommendations of the Stanford-Lancet Commission.
    Lancet. 2022;399:555-604.
    >> Share

  430. THE LANCET
    Managing the opioid crisis in North America and beyond.
    Lancet. 2022;399:495.
    >> Share

  431. BEYRER C
    Archbishop Desmond Tutu and the universality of health and human rights.
    Lancet. 2022;399:503-504.
    >> Share

    January 2022
  432. WU M, Wall EC, Carr EJ, Harvey R, et al
    Three-dose vaccination elicits neutralising antibodies against omicron.
    Lancet. 2022 Jan 19. pii: S0140-6736(22)00092.
    >> Share

  433. LAXMINARAYAN R
    The overlooked pandemic of antimicrobial resistance.
    Lancet. 2022 Jan 18. pii: S0140-6736(22)00087.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016